Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
96 articles with Altimmune, Inc.
-
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
-
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
9/7/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.
-
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
-
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
8/10/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update.
-
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
8/4/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
6/29/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
-
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
6/16/2021
Altimmune, Inc. today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801.
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
Altimmune to Present at Upcoming Scientific Conferences
4/29/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021.
-
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
4/1/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.
-
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
3/15/2021
New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months
-
Altimmune to Present at Upcoming Conferences
3/8/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021.
-
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
2/25/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced enrollment in a Phase 1 clinical trial of AdCOVID, a single-dose intranasal COVID-19 vaccine candidate.
-
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
2/25/2021
Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through the Phase 1 Clinical Trial Solidly Capitalized to Advance Pipeline Candidates with $216 Million in Cash and Short-Term Investments at Year-End
-
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
2/22/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
-
Altimmune Announces FDA Clearance of AdCOVID™ IND ApplicationEnrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week
2/17/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate.
-
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.